white shape

The intrigue Study

The intrigue study is testing the investigational drug DCC-2618 as a potential new treatment option for patients living with gastrointestinal stromal tumors (GIST). The study is being done to learn more about the safety of DCC-2618 and how well it works against cancer, as compared to Sutent® (sunitinib), in patients who have previously received imatinib.


calendar icon

How long is the intrigue study?

If you qualify to participate and choose to join the study, your participation may last up to 2 years. The actual duration will depend on a number of factors, including how your body responds to treatment and what you and the study doctor think is best for your health and well-being. Participation is always completely voluntary. You may decide to leave the study at any time, but while you are participating in the study, you must comply with all study requirements.


stethoscope icon

Who can participate in the intrigue study?

Approximately 358 people diagnosed with GIST will participate in the study worldwide. You may be eligible to join the study if you:

  • Are at least 18 years old
  • Have been diagnosed with GIST and received prior treatment with imatinib only
  • Are willing and able to comply with study procedures and restrictions

Click the “Can I participate?” button to access an intrigue study pre-screener and answer a few questions to find out if you may qualify to participate in the study.

Can I participate?

Depending on your responses to the pre-screener questions, you may be referred to a study site for further screening assessments to determine if you can participate in the intrigue study. The study doctor and staff will discuss additional criteria with you to determine if you qualify.


calendar icon

What drug is being studied?

DCC-2618 is an oral medication designed to treat GIST that are growing because of changes in specific genes. Genes are the instructions that tell a part of your body called a cell what to do. Cancer changes the genes so that the instructions are no longer correct. DCC-2618 is designed to inhibit signals from genes that cause cancer to grow. As an investigational drug, DCC-2618 has not been approved by the United States Food and Drug Administration (FDA) or any other regulatory agencies for sale or use by the public.

Sunitinib is approved by the FDA and other regulatory agencies for sale and use by the public.


checklist icon

What will happen if I join the study?

To join the intrigue study, you will first need to read and sign a study informed consent form. During the informed consent process, you will have the opportunity to ask as many questions as you want about the study.

After signing the informed consent form (ICF), you will undergo a screening process that includes tests and procedures to help determine if you qualify for study participation. You will also be asked about your medical history, previous anticancer treatments, medications you take, and other issues that may affect your ability to participate in the study.

Additional Information

More details can be found at ClinicalTrials.gov (NCT03673501).

Is the intrigue study an option for you or someone you know?

Find out now »